Skip to main content

Table 1 Demographics and baseline characteristics of study participants by cohort (all randomized participants)

From: Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors

  Cohort 1 Cohort 2 Cohort 3 Cohort 4 Total
(n = 6) (n = 6) (n = 6) (n = 6) (N = 24)
Age (years) 62 (4.3) 64 (6.4) 66 (1.7) 63 (3.3) 64 (4.3)
Sex (men), n (%) 6 (100.0) 5 (83.3) 6 (100.0) 5 (83.3) 22 (91.7)
Race, n (%)
 White 6 (100.0) 6 (100.0) 5 (83.3) 6 (100.0) 23 (95.8)
 Black or African American 0 0 1 (16.7) 0 1 (4.2)
Ethnicity, n (%)
 Not Hispanic or Latino 6 (100.0) 6 (100.0) 6 (100.0) 6 (100.0) 24 (100.0)
Weight (kg) 83 (10.8) 72 (8.3) 77 (5.6) 79 (10.6) 78 (9.6)
Height (cm) 176 (7.8) 170 (9.5) 171 (9.2) 173 (7.6) 172 (8.4)
BMI (kg/m2) 27.1 (3.8) 25 (2.3) 26.6 (2.7) 26.6 (3.5) 26.3 (3.0)
Total MMSE at screening 29.2 (0.8) 29.0 (1.3) 29.7 (0.5) 29.7 (0.8) 29.4 (0.9)
1-42 (pg/ml) 393.2 (26.4) 380.6 (44.1) 326.1 (75.4) 319.2 (97.6) 354.8 (70.6)
T-tau (pg/ml) 74.5 (20.0) 62.7 (28.9) 46.7 (20.6) 50.7 (21.9) 58.6 (24.3)
P-tau181P (pg/ml) 30.7 (8.2) 22.2 (4.9) 20.4 (6.9) 24.9 (13.0) 24.6 (9.1)
APOE ε4 carrier
 Yes 1 (16.7) 1 (16.7) 0 2 (33.3) 4 (16.7)
 No 4 (66.7) 3 (50.0) 5 (83.3) 4 (66.7) 16 (66.7)
 Unknown 1 (16.7) 2 (33.3) 1 (16.7) 0 4 (16.7)
  1. Data shown as mean (standard deviation), unless otherwise specified
  2. Cohort 1: immediate sampling, high frequency; cohort 2: delayed sampling, high frequency, procedure effect; cohort 3: ibuprofen, high frequency, inflammation effect; cohort 4: immediate sampling, low frequency. APOE, apolipoprotein E gene; BMI, body mass index; MMSE, mini–mental state examination; , amyloid beta; P-tau, phosphorylated tau; T-tau, total tau